Department of Breast Surgery, the First Affiliated Hospital of Xiamen University, Xiamen 361003, PR China.
Department of Radiation Oncology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center of Cancer Medicine, Guangzhou 510060, PR China.
Biomark Med. 2019 Feb;13(2):83-93. doi: 10.2217/bmm-2018-0396. Epub 2018 Dec 19.
To determine the effect of the 21-gene recurrence score (RS) on outcome and chemotherapy decision in breast invasive lobular carcinoma (ILC).
MATERIALS & METHODS: We included 6467 patients with early stage and estrogen receptor-positive ILC from the Surveillance, epidemiology, and end results database.
A total of 9.1, 31.4, and 70.1% of patients with low-, intermediate-, and high-risk RS groups received chemotherapy, respectively. A higher RS was independently associated with poor breast cancer-specific survival, and receipt of chemotherapy was not related to better breast cancer-specific survival in low-, intermediate-, or high-risk RS groups.
The 21-gene RS could impact chemotherapy decision making in early-stage ILC. However, adjuvant chemotherapy does not appear to improve outcome in high-risk RS cohort.
确定 21 基因复发评分 (RS) 对乳腺浸润性小叶癌 (ILC) 结局和化疗决策的影响。
我们纳入了来自监测、流行病学和最终结果数据库的 6467 例早期雌激素受体阳性 ILC 患者。
低、中、高危 RS 组患者分别有 9.1%、31.4%和 70.1%接受了化疗。较高的 RS 与较差的乳腺癌特异性生存独立相关，而在低、中、高危 RS 组中，接受化疗与更好的乳腺癌特异性生存无关。
21 基因 RS 可能影响早期 ILC 的化疗决策。然而，辅助化疗似乎并不能改善高危 RS 组的预后。
